FINNENCE ▪ THE WIRE FILE
THE WIRE · № 75801
News■ Unclear/unknown
Flo Health and Google Health Join Forces to Put Women's Health at the Center of Wearable Tracking and Personalized Coaching
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Google Health investment in women's health wearables expands its consumer health data footprint.
Google deepens health wearables via Flo partnership
CATALYST TO WATCH
Co-branded product launch details
MAIN RISK
Privacy concerns could slow integration
FULL DISPATCH
Multi-year partnership, backed by a strategic investment from Google Health, to include consent-first integration, future co-branded products and women's health research LONDON, Oct. 12, 2026 /PRNewswire/ -- Flo Health, the #1 women's health platform worldwide, announces today a...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDAlphabet · GOOGL
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Immorta Bio Pioneers AI-Designed Senolytic Immunotherapy Targeting Diseases of Aging2026-10-12 13:22 UTC
Immorta Bio Pioneers AI-Designed Senolytic Immunotherapy Targeting Diseases of Aging2026-10-12 13:22 UTC
←CORRELATIONshares GOOGL
Naver Map to offer voice guidance on Meta, Google, Samsung smart glasses2026-10-12 04:45 UTC
Naver Map to offer voice guidance on Meta, Google, Samsung smart glasses2026-10-12 04:45 UTC
←CORRELATIONshares Healthcare
City Thera targets $175 million IPO to advance RNA drugs2026-10-12 10:23 UTC
City Thera targets $175 million IPO to advance RNA drugs2026-10-12 10:23 UTC
←CORRELATIONshares Healthcare
Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS)2026-10-12 10:29 UTC
Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS)2026-10-12 10:29 UTC
←CORRELATIONshares Healthcare
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer2026-10-12 11:00 UTC
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer2026-10-12 11:00 UTC
←CORRELATIONshares Healthcare
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 202026-10-12 11:05 UTC
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 202026-10-12 11:05 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.